$3.41
0.00% yesterday
Nasdaq, Apr 02, 03:30 pm CET
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Opthea Limited - ADR Stock price

$3.41
-1.70 33.27% 1M
-1.19 25.87% 6M
-0.52 13.18% YTD
-0.54 13.67% 1Y
-2.83 45.35% 3Y
-17.95 84.04% 5Y
+2.01 143.57% 10Y
Nasdaq, Closing price Wed, Apr 02 2025
+0.00 0.00%
ISIN
US68386J2087
Symbol
OPT
Sector
Industry

Key metrics

Market capitalization $524.84m
Enterprise Value $615.67m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 6,840.78
P/S ratio (TTM) P/S ratio 5,831.56
P/B ratio (TTM) P/B ratio negative
Revenue growth (TTM) Revenue growth -25.10%
Revenue (TTM) Revenue $90.00k
EBIT (operating result TTM) EBIT $-182.96m
Free Cash Flow (TTM) Free Cash Flow $-163.36m
EPS (TTM) EPS $-2.32
P/E forward negative
P/S forward 820.32
EV/Sales forward 962.29
Short interest 0.46%
Show more

Is Opthea Limited - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,794 stocks worldwide.

Opthea Limited - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

8 Analysts have issued a Opthea Limited - ADR forecast:

1x Buy
13%
5x Hold
63%
2x Sell
25%

Analyst Opinions

8 Analysts have issued a Opthea Limited - ADR forecast:

Buy
13%
Hold
63%
Sell
25%

Financial data from Opthea Limited - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Dec '24
+/-
%
0.09 0.09
25% 25%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 22 22
10% 10%
24,300%
- Research and Development Expense 161 161
11% 11%
179,033%
- -
-
-
- Depreciation and Amortization - -
-
-
EBIT (Operating Income) EBIT -183 -183
11% 11%
-203,291%
Net Profit -255 -255
58% 58%
-283,778%

In millions USD.

Don't miss a Thing! We will send you all news about Opthea Limited - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Opthea Limited - ADR Stock News

Neutral
GlobeNewsWire
4 days ago
ShORe Phase 3 topline results accelerated; trial did not meet primary endpoint of mean change in BCVA from baseline to week 52
Neutral
GlobeNewsWire
11 days ago
COAST Phase 3 trial failed to meet primary endpoint of mean change in BCVA from baseline to week 52 Opthea considering impact of negative trial results under its Development Funding Agreement and on the Company as a going concern MELBOURNE, Australia and PRINCETON, N.J., March 24, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT, “Opthea”, the “Company”), a clinical-stage biopharmaceuti...
Neutral
GlobeNewsWire
about one month ago
Baseline angiographic lesion characteristics predictive of clinical response Published in peer-reviewed journal Ophthalmic Surgery, Lasers and Imaging Retina MELBOURNE, Australia and PRINCETON, N.J., March 03, 2025 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and prog...
More Opthea Limited - ADR News

Company Profile

Opthea Ltd. is a clinical stage biopharmaceutical company that engages in the development of biological therapeutics for the treatment of progressive retinal diseases. It targets to treat neovascular age-related macular degeneration (wet AMD) and diabetic macular edema, which causes visual impairment among elderly and diabetic patients. The company was founded on October 17, 1984 and is headquartered in South Yarra, Australia.

Head office Australia
CEO Frédéric Guerard
Founded 1984
Website www.opthea.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today